Damora Therapeutics (DMRA) Income from Continuing Operations (2019 - 2026)
Damora Therapeutics (DMRA) posted Income from Continuing Operations of 27783000.0 for Q1 2026, up 85.89% on a QoQ basis from 196876000.0 in Q4 2025, and down 996.84% year-over-year from 3097871.15 in Q1 2025.
Damora Therapeutics (DMRA) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Damora Therapeutics' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 27783000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 996.84% year-over-year to 27783000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 231229000.0 (down 1150.22% YoY) and the FY2025 annual result came in at 205979000.0, down 860.77% from the prior year.
- Income from Continuing Operations was 27783000.0 for Q1 2026 at Damora Therapeutics, up from 196876000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1667000.0 in Q4 2023 and bottomed at 196876000.0 in Q4 2025.
- A 5-year average of 20546617.24 and a median of 8136000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations surged 112.19% — and 2025, when it plunged 2820.58%.
- Damora Therapeutics' Income from Continuing Operations stood at 13680000.0 in 2022, then jumped by 112.19% to 1667000.0 in 2023, then plunged by 504.38% to 6741000.0 in 2024, then plunged by 2820.58% to 196876000.0 in 2025, then surged by 85.89% to 27783000.0 in 2026.
- Business Quant data shows DMRA's Income from Continuing Operations at 27783000.0 in Q1 2026, 196876000.0 in Q4 2025, and 3133000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Damora Therapeutics | 1.00 Bn | 798.11 Mn | - | -27.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.78 Mn |
| Dec 31, 2025 | -196.88 Mn |
| Sep 30, 2025 | -3.13 Mn |
| Jun 30, 2025 | -3.44 Mn |
| Mar 31, 2025 | -2.53 Mn |
| Dec 31, 2024 | -6.74 Mn |
| Sep 30, 2024 | -3.88 Mn |
| Jun 30, 2024 | -5.34 Mn |
| Mar 31, 2024 | -5.48 Mn |
| Dec 31, 2023 | 1.67 Mn |
| Sep 30, 2023 | -8.14 Mn |
| Jun 30, 2023 | -10.74 Mn |
| Mar 31, 2023 | -14.92 Mn |
| Dec 31, 2022 | -13.68 Mn |
| Sep 30, 2022 | -13.76 Mn |
| Jun 30, 2022 | -17.24 Mn |
| Mar 31, 2022 | -17.28 Mn |
| Dec 31, 2021 | -13.58 Mn |
| Sep 30, 2021 | -15.00 Mn |
| Jun 30, 2021 | -16.27 Mn |